StockNews.AI

Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue

StockNews.AI • 3 hours

MIODxN/A
High Materiality8/10

Information

Research-use-only offerings are commercially available, enabling immediate product and service reven...

Original source

AI Summary

Profusa, Inc. has launched its Healthcare Research version of the Lumee tissue oxygen monitoring, targeting the growing contract research organization (CRO) market, expected to generate immediate revenue. This strategic initiative capitalizes on increasing demand for real-time biological data in drug development, positioning Profusa for significant growth in a market expanding at a 7% CAGR.

Sentiment Rationale

The introduction of a sought-after product within a rapidly expanding market typically leads to positive stock performance. Historical examples include companies in similar sectors that reported significant revenue spikes following strategic launches.

Trading Thesis

Invest in PFSA for strong upside potential in the CRO market over the next 12 months.

Market-Moving

  • Immediate revenue generation expected from new Healthcare Research offerings.
  • CRO market projected to exceed $91.2 billion by 2034.
  • Increased demand for predictive biological data among pharmaceutical companies.
  • Appointment of experienced executive to lead commercialization efforts.

Key Facts

  • Profusa launches tissue oxygen monitoring for CRO market.
  • Service-based revenue expected from Healthcare Research offerings.
  • Market for CRO services projected at $47.9 billion in 2025.
  • Company appointed new head for commercial healthcare business.
  • Lumee technology allows real-time biological data for drug development.

Companies Mentioned

  • Profusa, Inc. (PFSA): Launch of Lumee technology may enhance revenue prospects.
  • MIODx (N/A): Former COO Sean Givens brings experience in drug development.

Corporate Developments

This news falls under 'Corporate Developments' as it pertains to Profusa's strategic launch aimed at expanding its market reach and revenue potential in the CRO sector. This initiative leverages existing technology to meet growing industry demands, crucial for investors to monitor.

Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue

BERKELEY, Calif., Jan. 16, 2026 – Profusa, Inc. (Nasdaq: PFSA), a pioneering digital health company, has announced the launch of its Lumee™ tissue oxygen monitoring system aimed at the contract research organization (CRO) market. This innovative offering allows Profusa to generate immediate service-based revenue while targeting a global CRO market projected to reach approximately $47.9 billion in 2025, with ongoing growth at a 7% CAGR.

Overview of Lumee™ Tissue Oxygen Monitoring System

Profusa’s Lumee tissue oxygen products are now commercially available, providing CRO partners with rapid deployment capabilities. This technology integration enhances the existing study designs of these organizations, enabling them to deliver differentiated services to clients while minimizing implementation risks.

The CRO and pharmaceutical services market is currently experiencing significant growth, fueled by increased research and development investments, regulatory momentum concerning new approach methodologies (NAMs), and the imperative to mitigate late-stage development risks. Industry forecasts suggest that the global pharmaceutical CRO market could expand to over $91.2 billion by 2034.

Key Features and Applications

By offering Lumee™ as commercial research-use-only (RUO) kits, Profusa provides researchers and R&D teams with access to continuous and real-time measurements of tissue oxygenation. This data is critical across various applications, such as:

  • Advanced in vitro and organ-on-chip models
  • Preclinical pharmacology and toxicology studies
  • Translational research programs

Additionally, the Lumee tissue oxygen system facilitates research into complex biological processes, including:

  • Tissue oxygenation dynamics in wound healing
  • Tumor microenvironments in oncology

This integration allows pharmaceutical customers to acquire biologically relevant data that surpasses traditional endpoint assays, enhancing decision-making and drug development efficiency.

Leadership and Market Positioning

To capitalize on the growing market demand, Profusa has appointed Sean Givens as the Head of Government and Healthcare Research Business. Mr. Givens brings over 20 years of experience in government accounting and contracting, complemented by extensive operations experience in consumer electronics and medical devices.

“This is a natural and timely extension of Profusa’s platform. Our sensors are validated, ready to ship, and already generating strong interest across the industry,” stated Mr. Givens. “By partnering with CROs, we can help accelerate better drug development decisions while creating a meaningful, near-term revenue stream for Profusa.”

About Profusa

Headquartered in Berkeley, California, Profusa is at the forefront of developing a new generation of tissue-integrated sensors designed to provide continuous, actionable, medical-grade data for both personal and clinical use. The company strives to deliver long-lasting, injectable, and affordable biosensors alongside an intelligent data platform aimed at enhancing health outcomes.

For more information about Profusa and its innovative products, visit profusa.com.

Forward-Looking Statements

Certain statements in this announcement may be deemed "forward-looking" in accordance with the U.S. Private Securities Litigation Reform Act of 1995. These statements often involve risks and uncertainties that may result in actual results differing materially from those anticipated.

Contact Information

For inquiries related to the new offering, please reach out to:

Related News